Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy

Xiaosheng Zhuang,Chi Chen,Zhenyu Liu,Liulu Zhang,Xuezhi Zhou,Minyi Cheng,Fei Ji,Teng Zhu,Chuqian Lei,Junsheng Zhang,Jingying Jiang,Jie Tian,Kun Wang
DOI: https://doi.org/10.1016/j.tranon.2020.100831
IF: 4.803
2020-11-01
Translational Oncology
Abstract:Breast cancers show different regression patterns after neoadjuvant chemotherapy. Certain regression patterns are associated with more reliable margins in breast-conserving surgery. Our study aims to establish a nomogram based on radiomic features and clinicopathological factors to predict regression patterns in breast cancer patients.We retrospectively reviewed 144 breast cancer patients who received neoadjuvant chemotherapy and underwent definitive surgery in our center from January 2016 to December 2019. Tumor regression patterns were categorized as type 1 (concentric regression + pCR) and type 2 (multifocal residues + SD + PD) based on pathological results. We extracted 1158 multidimensional features from 2 sequences of MRI images. After feature selection, machine learning was applied to construct a radiomic signature. Clinical characteristics were selected by backward stepwise selection. The combined prediction model was built based on both the radiomic signature and clinical factors. The predictive performance of the combined prediction model was evaluated.Two radiomic features were selected for constructing the radiomic signature. Combined with two significant clinical characteristics, the combined prediction model showed excellent prediction performance, with an area under the receiver operating characteristic curve of 0.902 (95% confidence interval 0.8343–0.9701) in the primary cohort and 0.826 (95% confidence interval 0.6774–0.9753) in the validation cohort.Our study established a unique model combining a radiomic signature and clinicopathological factors to predict tumor regression patterns prior to the initiation of NAC. The early prediction of type 2 regression offers the opportunity to modify preoperative treatments or aids in determining surgical options.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to predict the regression pattern of breast tumors after neoadjuvant chemotherapy (NAC). Specifically, the study aims to establish a nomogram based on multi - parameter MRI radiomics analysis and clinicopathological factors to predict the tumor regression pattern in breast cancer patients. These patterns are crucial for determining the suitability for breast - conserving surgery (BCS), as different regression patterns are related to the safety of surgical margins and the postoperative recurrence rate. By predicting the tumor regression pattern early, more appropriate treatment plans can be provided for patients, unnecessary surgical risks can be reduced, and the treatment effect can be improved. The research background indicates that neoadjuvant chemotherapy is playing an increasingly important role in the comprehensive treatment of locally advanced breast cancer, with the main purpose of reducing the tumor stage and increasing the possibility of breast - conserving surgery. However, the tumor regression patterns after chemotherapy are diverse, including pathological complete response (pCR), single - focus shrinkage, multi - focus residue, main lesion with satellite lesions, stable disease (SD), and progressive disease (PD). Among them, single - focus residue and pCR are more conducive to breast - conserving surgery, while multi - focus residue, SD, and PD are more likely to require total mastectomy. The research objective of the paper is to establish a model that can predict the tumor regression pattern by combining radiomics features and clinicopathological factors, so as to predict the patient's regression type before the start of NAC and provide support for clinical decision - making. This will not only help optimize the treatment plan, but also reduce the additional surgical risks caused by poor treatment response.